%20--%3e%3csvg%20version='1.1'%20id='Capa_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%20114.1%2024.9'%20style='enable-background:new%200%200%20114.1%2024.9;'%20xml:space='preserve'%3e%3cstyle%20type='text/css'%3e%20.st0{fill:%23FFFFFF;}%20%3c/style%3e%3cg%3e%3cg%3e%3cg%3e%3cpath%20class='st0'%20d='M0.6,0.1c1.8,0,3.6,0.1,4.6,0.1c0.8,0,2.8-0.1,4-0.1c0.5,0,0.8,0.1,0.8,0.3S9.8,0.7,9.4,0.7%20c-0.4,0-0.3,0-0.7,0.1C7.9,0.9,7.6,1.4,7.5,2.5c-0.1,1-0.1,1.9-0.1,6.8v4.5c0,4.6,0.9,6.6,2.5,7.9c1.5,1.2,2.7,1.3,3.8,1.3%20c1.4,0,3-0.5,4.3-1.7c1.8-1.8,1.9-4.6,1.9-7.9V9.5c0-4.9,0-5.7-0.1-6.8c-0.1-1.1-0.3-1.6-1.4-1.8c-0.3-0.1-0.7-0.1-0.9-0.1%20c-0.4,0-0.6-0.1-0.6-0.3s0.2-0.3,0.7-0.3c1.7,0,3.8,0.1,3.8,0.1c0.4,0,2.4-0.1,3.8-0.1c0.5,0,0.7,0.1,0.7,0.3s-0.2,0.3-0.6,0.3%20s-0.4,0-0.8,0.1c-0.8,0.2-1.1,0.7-1.2,1.8c-0.1,1-0.1,1.9-0.1,6.8v3.4c0,3.6-0.4,7.3-3.1,9.6c-2.3,2-4.9,2.3-7,2.3%20c-1.8,0-6,0-8.4-2.2c-1.7-1.5-2.9-3.8-2.9-8.4V9.5c0-4.9,0-5.7,0-6.8c0-0.9,0.1-1.4-0.3-1.8C1.3,0.8,1.2,0.8,0.9,0.8S0,0.7,0,0.5%20C0.1,0.2,0.2,0.1,0.6,0.1'/%3e%3cpath%20class='st0'%20d='M31.3,21.2c-3.2-2.7-4-6.2-4-9.2c0-2.2,0.7-5.8,3.8-8.5c2.3-2.1,5.3-3.3,10.2-3.3c2,0,3.2,0.1,4.7,0.3%20c1.2,0.2,2.3,0.5,3.2,0.6c0.4,0,0.5,0.2,0.5,0.4c0,0.3-0.1,0.7-0.2,1.7c-0.1,1,0,2.7-0.1,3.4c0,0.5-0.1,0.8-0.4,0.8%20c-0.3,0-0.3-0.3-0.3-0.7c0-0.9-0.5-2.1-1.2-2.9c-1-1.1-2.7-1.8-5.6-1.8c-2.8,0-3.9,0.7-5.3,2c-2.3,2.1-3,5.1-3,8.1%20c0,7.4,5.8,11.2,10.1,11.2c2.9,0,3.1-0.1,4.4-1.5c0.6-0.6,0.9-1.9,1-2.4c0.1-0.5,0.2-0.7,0.5-0.7c0.2,0,0.3,0.2,0.3,0.5%20c0,0.4-0.4,3.1-0.8,4.1c-0.2,0.6-0.3,0.7-0.8,0.9c-1.3,0.5-3.8,0.8-5.8,0.8C37.9,24.6,34.2,23.6,31.3,21.2'/%3e%3cpath%20class='st0'%20d='M86,0.8c0.3-0.6,0.8-0.7,0.8-0.7c0.3,0,0.6,0.1,0.9,0.6l8.8,17.7l8.6-17.4c0.3-0.5,0.7-0.8,0.9-0.8%20c0.4,0,0.8,0.4,0.8,0.9l2.9,19.4c0.3,2,0.7,2.9,1.6,3.2c0.9,0.3,1.1,0.4,1.5,0.4c0.3,0,0.5,0,0.5,0.2c0,0.3-0.4,0.4-0.8,0.4%20c-0.8,0-5.3-0.1-6.6-0.2c-0.8-0.1-0.9-0.2-0.9-0.4s0.1-0.3,0.4-0.4c0.2-0.1,0.3-0.5,0.2-1.3l-2-13.8h0.1l-7,14.3%20c-0.8,1.5-1,1.7-1.5,1.7S94.4,24,94,23.1c-0.8-1.4-3.4-6.3-3.8-7.1c-0.3-0.7-2.3-4.6-3.4-6.9h0.4l-1.7,12.5%20c-0.1,0.6-0.1,0.9-0.1,1.5c0,0.6,0.5,0.8,0.9,1c0.6,0.1,1,0.2,1.3,0.2c0.3,0,0.5,0.1,0.5,0.2c0,0.3-0.3,0.4-0.8,0.4%20c-1.4,0-2.8-0.1-3.4-0.1c-0.7,0-2.2,0.1-3.2,0.1c-0.3,0-0.6-0.1-0.6-0.4c0-0.2,0.2-0.2,0.5-0.2s0.5,0,0.9-0.1%20c0.9-0.2,1-1.7,1.2-2.7L86,0.8z'/%3e%3cpath%20class='st0'%20d='M61.1,17.4c-0.3,0.1-0.9,0.3-1.3,0.9l-1.2,2.7C58.2,21.9,58,22.6,58,23c0,0.6,0.3,0.9,1.3,0.9h0.5%20c0.4,0,0.5,0.1,0.5,0.3c0,0.3-0.2,0.3-0.6,0.3c-1,0-2.4-0.1-3.5-0.1c-0.4,0-2.2,0.1-3.8,0.1c-0.5,0-0.7-0.1-0.7-0.3%20s0.1-0.3,0.4-0.3c0.3,0,0.8,0,1-0.1c1.5-0.2,2-1.6,2.6-3.2l8.2-19.7C64.2,0,65,0,65.1,0c0.3,0,0.6,0.2,1,1%20C67,2.7,72,15.6,74.2,20.4c1.2,2.8,2.2,3.3,2.8,3.4c0.5,0.1,0.6,0.1,0.9,0.1c0.3,0,0.5,0,0.5,0.3s-0.3,0.3-1.5,0.3%20c-1.1,0-3.6,0-6.1-0.1c-0.6,0-0.9,0-0.9-0.3c0-0.2,0.1-0.3,0.5-0.3c0.2-0.1,0.5-0.4,0.3-0.8l-2.2-4.8c-0.1-0.2-0.8-0.8-1.3-0.9%20C67.1,17.4,61.2,17.4,61.1,17.4%20M61.1,15.4c1.1,0.1,4.2,0.1,5.7,0c0.3,0,0.5-0.4,0.4-0.7l-2.7-7.8c-0.1-0.1-0.1-0.3-0.2-0.3%20c-0.1,0-0.2,0.2-0.2,0.3l-3.2,7.8C60.7,15,60.7,15.3,61.1,15.4'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
Investigación Traslacional del Cáncer
Artículos JCR
Enrique González Billalabeitia, Vincenza Conteduca, Daniel Wetterskog, MTA Sharabiani, Enrique Grande, Maria Piedad Fernandez-Perez, Anu Jayaram, Samantha Salvi, Daniel Castellano, Alesandro Romanel, C Lolli, V Casadio, G Gurioli, D Amadori, Albert Font, Sergio Vazquez-Estevez, Arancha González del Alba, Begoña Mellado, Ovidio Fernández-Calvo, Maria Jose Méndez-Vidal, Miguel Angel Climent, Ignacio Duran, Enrique Gallardo, Alvaro Rodriguez, Carmen Santander, Maria Isabel Sáez, Javier Puente, D Gasi Tandafelt, Anna Wingate, D Dearnaley, Franchesca Demichelis, Enrique González-Billalabeitia, Gerhart Attard. 2017. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Annals of Oncology. Volumen 28. Páginas 1805 - 1816.
Enrique González Billalabeitia, A González del Alba, JA Arranz, J Puente, MJ Méndez-Vidal, E Gallardo, E Grande, B Pérez-Valderrama, E González-Billalabeitia, M Lázaro-Quintela, A Pinto, N Lainez, JM Piulats, E Esteban, JP Maroto-Rey, JA García, Cristina Suarez. 2017. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment.. Critical Review Oncology Hematology. Volumen 113. Páginas 171 - 190.
Enrique González Billalabeitia, IK Vila, Y Yao, G Kim, W Xia, H Kim, SJ Kim, MK Park, JP Hwang, Enrique González-Billalabeitia, MC Hung, Su Jung Song, Min Sup Song. 2017. A UBE2O-AMPKα2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy. Cancer Cell. Volumen 31. Páginas 208 - 224.
Enrique González Billalabeitia, JL Pérez-Gracia, MF Sanmamed, A Bosch, A Patiño-García, KA Schalper, V Segura, J Bellmunt, J Tabernero, CJ Sweeney, TK Choureiri, M Martín, JP Fusco, ME Rodríguez-Ruiz, A Calvo, C Prior, Luis Paz-Ares, R Pio, Enrique González-Billalabeitia, A González-Hernández, D Paez, JM Piulats, A Gurpide, M Andueza, G de Velasco, R Pazo, Enrique Grande, P Nicolas, F Abad-Santos, J García-Donas, Daniel Castellano, MJ Pajares, Cristina Suarez, Ramón Colomer, LM Montuenga, Ignacio Melero. 2017. Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews. Volumen 53. Páginas 79 - 97.
Enrique González Billalabeitia, Ginés Luengo Gil, Asunción Chaves Benito, Elena García Martínez, Elisa García Garre, Vicente Vicente García, Francisco Ayala de la Peña. 2015. Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis. Breast Cancer Research and Treatment. Volumen 151. Páginas 577 - 587.
Enrique González Billalabeitia, Elena Garcia Martinez, Gines Luengo Gil, Asuncion Chaves Benito, Maria Angeles Vicente Conesa, Teres García García, Elisa García Garre, Vicente Vicente García, Francisco Ayala de la Peña. 2014. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.. Breast Cancer Res. Volumen 16. Páginas 488 - 488.
Enrique González Billalabeitia, R Lecumberri, G López Vivanco, A Font, E González Billalabeitia, A Gurpide, J Gomez Codina, D Isla, A Galán, I Bover, M Domine, V Vicente, R Rosell, E Rocha. 2013. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study.. Thromb Res. Volumen 132. Páginas 666 - 670.
Enrique González Billalabeitia, Guocan Wang, Andrea Lunardi, J Zhang, Z Chen, Ugo Ala, KA Webster, Yvone Tay, Ainara Eguia, DR Shaffer, B Carver, XS Liu, Ricardo Taulli, WP Kuo, Caterina Nardella, Sabina Signoretti, C Cordón Cardo, WL Gerald, Pier Paolo Pandolfi. 2013. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Revista: Nat Genet. 2013 Jul;45(7):739-46.. Nature Genetics. Volumen 45. Páginas 739 - 746.
Enrique González Billalabeitia, MA Vicente Conesa, E García Martínez, Asunción Chaves Benito, Teresa García Garcia, Vicente Vicente, Francisco Ayala de la Peña. 2011. Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy.. Breast. Volumen 21. Páginas 468 - 474.
Enrique González Billalabeitia, Alberto Carmona Bayonas, J Gomez, M Canteras, A Navarrete, ML Gonzálvez, Vicente Vicente, Francisco Ayala de la Peña. 2011. Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients.. Br J Cancer. Volumen 105. Páginas 612 - 617.
Enrique González Billalabeitia, J Calzas, Daniel Castellano, Cesar Mendiola, Susana Bezares, Vicente Valentín, Javier Hornedo, Eva Ciruelo, Hernan Cortés Funes. 2009. Long-term follow-up of an anthracycline-containing metronomic chemotherapy schedule in advanced breast cancer.. Breast J. Volumen 15. Páginas 551 - 553.
Enrique González Billalabeitia, Ricardo Hitt, Jesús Fernández, Esther Conde, Francisco Martínez Tello, R Enriquez de Salamanca, Hernán Cortés Funes. 2009. Pre-treatment serum lactate dehydrogenase level is an important prognostic factor in high-grade extremity osteosarcoma.. Clin Transl Oncol. Volumen 11. Páginas 479 - 483.
Enrique González Billalabeitia, Marta Zafra, Francisco Ayala, Elena Vicente, P González Cabezas, Teresa García, JA Macías, Vicente Vicente. 2008. Impact of whole-body 18F-FDG PET on diagnostic and therapeutic management of Medical Oncology patients.. Eur J Cancer. Volumen 44. Páginas 1678 - 1683.
Enrique González Billalabeitia, Maria del mar Osma, Francisco J Ortuño, Andrés Jerez, Francisco Ayala, Vicente Vicente. 2007. Transient massive peripheral blood blastosis in patient with renal clear-cell carcinoma after treatment with high-dose recombinant interleuklin-2.. Lancet Oncol. Volumen 8. Páginas 275 - 276.
Enrique González Billalabeitia, Miguel Quintela Fandino, Cristina Gravalos, Enrique González, Adelaida García Velasco, Hernan Cortés Funes. 2005. Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer. Anticancer Drugs. Volumen 16. Páginas 31 - 38.
Capítulos de libro
Enrique González Billalabeitia, Inmaculada Ballester. 2017. Perfil de seguridad. Papel de los niveles de imatinib en sangre. Diego Marín. Páginas 501 - 515.
Enrique González Billalabeitia, Renato Salguero Aguilar, Francisco Ayala de la Peña. 2015. Cáncer de prostata resistente a la castración metastásico sintomático. Permanyer. Páginas 33 - 46.
Enrique González Billalabeitia, Hernán Cortés Funes. 2002. Efecto antiangiogénico de la quimioterapia citotóxica. You & US. Páginas 67 - 74.
Otros Artículos
Enrique González Billalabeitia, Beatriz Paumard-Hernández, O Calvete, L Inglada Pérez, H Tejero, F Al-Shahrour, G Pita, A Barroso, J Carlos Triviño, M Urioste, C Valverde, V Quiroga, J Francisco Rodríguez Moreno, A Fernández Aramburo, C López, P Maroto, J Sastre, M José Juan Fita, I Duran, I Lorenzo-Lorenzo, P Iranzo, X García Del Muro, S Ros, F Zambrana, A María Autran, J Benítez. 2018. Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer. International Journal of Cancer. Volumen 143. Páginas 1954 - 1962.
Enrique González Billalabeitia, Jorge Aparicio, Alfonso Sanchez-Muñoz, Josep Guma, Montse Domenech, JA Meana, J García-Sanchez, R Bastus, Regina Girones, Enrique Gonzalez-Billalabeitia, N Sagastibelza, S Ochenduszko, A Sanchez, Josefa Terrasa, Josep Ramon Germa-Lluch, Xavier García del Muro. 2018. A Risk-Adapted Approach to Patients with Stage I Seminoma according to the Status of Rete Testis: The Fourth Spanish Germ Cell Cancer Group Study. Oncology. Volumen 95. Páginas 8 - 12.
Enrique González Billalabeitia, Arancha Sanchez, Enrique González, J Camarero. 2013. Emerging Therapies in Metastatic Castration-Resistant Prostate Cancer: A Regulatory Perspective. Global Journal of Oncologists. Volumen 1. Páginas 13 - 19.
Enrique González Billalabeitia, Antonio Jimeno, Adelaida García Velasco, Olga del Val, Susana Hernando, Rosario Hernández, Alfonso Sánchez Muñoz, Ana López Martín, Ignacio Durán, Luis Robles, Hernan Cortés Funes, Luis Paz Ares. 2004. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia.. Cancer. Volumen 100. Páginas 2462 - 2469.
Enrique González Billalabeitia, Alfonso Sánchez Muñoz, F López Medrano, V Artiles Valle, Antonio Jimeno Largo. 2003. Extensive acute intestinal ischemia in a patient with colon carcinoma with local recurrence. Rev Clin Esp. Volumen 203. Páginas 487 - 490.
Proyectos competitivos
SOG-MIE-2014-04. Estudio fase II multicéntrico y observacional que analiza el valor predictivo de respuesta a enzalutamida del gen de fusión TMPRSS2-ETS en pacientes con CPRC metastásico no tratados previamente con quimioterapia. Grupo Español de Tumores Urologicos (SOGUG). (2015-2017)
Estudio co-clínico en el cancer de próstata. Instituto de salud carlos III (. (2010-2012)